Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.
Cortes CP, Wehbe FH, McGowan CC, Shepherd BE, Duda SN, Jenkins CA, Gonzalez E, Carriquiry G, Schechter M, Padgett D, Cesar C, Madero JS, Pape JW, Masys DR, Sterling TR; Caribbean, Central American, South American Network for HIV Research of the International Epidemiologic Databases to Evaluate AIDS. Cortes CP, et al. Among authors: madero js. PLoS One. 2013 Sep 16;8(9):e74057. doi: 10.1371/journal.pone.0074057. eCollection 2013. PLoS One. 2013. PMID: 24066096 Free PMC article.
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean.
Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, Cahn P, Wolff M, Pape JW, Padgett D, Madero JS, Gotuzzo E, Masys DR, Shepherd BE. Tuboi SH, et al. Among authors: madero js. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):615-23. doi: 10.1097/QAI.0b013e3181a44f0a. J Acquir Immune Defic Syndr. 2009. PMID: 19430306 Free PMC article.
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.
Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff M, Pape JW, Leger P, Padgett D, Madero JS, Gotuzzo E, Sued O, McGowan CC, Masys DR, Cahn PE; Caribbean, Central and South America Network for HIV Research (CCASAnet) Collaboration of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program. Cesar C, et al. Among authors: madero js. PLoS One. 2010 Jun 1;5(6):e10490. doi: 10.1371/journal.pone.0010490. PLoS One. 2010. PMID: 20531956 Free PMC article.
Use of third line antiretroviral therapy in Latin America.
Cesar C, Shepherd BE, Jenkins CA, Ghidinelli M, Castro JL, Veloso VG, Cortes CP, Padgett D, Crabtree-Ramirez B, Gotuzzo E, Fink V, Duran A, Sued O, McGowan CC, Cahn P; Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet). Cesar C, et al. PLoS One. 2014 Sep 15;9(9):e106887. doi: 10.1371/journal.pone.0106887. eCollection 2014. PLoS One. 2014. PMID: 25221931 Free PMC article.
Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries.
Ballif M, Nhandu V, Wood R, Dusingize JC, Carter EJ, Cortes CP, McGowan CC, Diero L, Graber C, Renner L, Hawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Egger M, Fenner L; International epidemiological Databases to Evaluate AIDS (IeDEA). Ballif M, et al. Int J Tuberc Lung Dis. 2014 Nov;18(11):1327-36. doi: 10.5588/ijtld.14.0106. Int J Tuberc Lung Dis. 2014. PMID: 25299866 Free PMC article.
Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
Carriquiry G, Fink V, Koethe JR, Giganti MJ, Jayathilake K, Blevins M, Cahn P, Grinsztejn B, Wolff M, Pape JW, Padgett D, Madero JS, Gotuzzo E, McGowan CC, Shepherd BE. Carriquiry G, et al. Among authors: madero js. J Int AIDS Soc. 2015 Jul 10;18(1):20016. doi: 10.7448/IAS.18.1.20016. eCollection 2015. J Int AIDS Soc. 2015. PMID: 26165322 Free PMC article.
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.
Cesar C, Jenkins CA, Shepherd BE, Padgett D, Mejía F, Ribeiro SR, Cortes CP, Pape JW, Madero JS, Fink V, Sued O, McGowan C, Cahn P; Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program. Cesar C, et al. Among authors: madero js. Lancet HIV. 2015 Nov;2(11):e492-500. doi: 10.1016/S2352-3018(15)00183-6. Epub 2015 Oct 22. Lancet HIV. 2015. PMID: 26520929 Free PMC article.
A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts.
Althoff KN, Rebeiro PF, Hanna DB, Padgett D, Horberg MA, Grinsztejn B, Abraham AG, Hogg R, Gill MJ, Wolff MJ, Mayor A, Rachlis A, Williams C, Sterling TR, Kitahata MM, Buchacz K, Thorne JE, Cesar C, Cordero FM, Rourke SB, Sierra-Madero J, Pape JW, Cahn P, McGowan C; North American Aids Cohort Collaboration on Research and Design (NA-ACCORD) and Caribbean, Central and South America Network for Hiv Epidemiology (CCASAnet). Althoff KN, et al. J Int AIDS Soc. 2016 Apr 4;19(1):20707. doi: 10.7448/IAS.19.1.20707. eCollection 2016. J Int AIDS Soc. 2016. PMID: 27049052 Free PMC article.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Cahn P, et al. Among authors: madero js. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Lancet. 2019. PMID: 30420123 Clinical Trial.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. Among authors: madero js. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
31 results